Harmony Biosciences Holdings (HRMY) Net Cash Flow Growth (1y) (2020 - 2026)
Harmony Biosciences Holdings (HRMY) Net Cash Flow Growth (1y) (2020 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | -88.82% |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 301.06% |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 453.08% |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | -125.22% |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | Harmony Biosciences Holdings | 2.09 Bn | 1.57 Bn | 170.88 Mn | -553.10% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -553.10% |
| Dec 31, 2025 | 60.74% |
| Sep 30, 2025 | 44.07% |
| Jun 30, 2025 | 463.74% |
| Mar 31, 2025 | 68.83% |
| Dec 31, 2024 | 607.89% |
| Sep 30, 2024 | 874.83% |
| Jun 30, 2024 | -154.17% |
| Mar 31, 2024 | -51.74% |
| Dec 31, 2023 | 26.40% |
| Sep 30, 2023 | -71.03% |
| Jun 30, 2023 | 140.59% |
| Mar 31, 2023 | 550.34% |
| Dec 31, 2022 | -139.37% |
| Sep 30, 2022 | -17.35% |
| Jun 30, 2022 | -35.01% |
| Mar 31, 2022 | 88.78% |
| Dec 31, 2021 | 547.29% |
| Sep 30, 2021 | -79.36% |
| Jun 30, 2021 | 288.60% |